FDA EYES NEW STRATEGIES TO SPUR CELL AND GENE THERAPY DEVELOPMENT.

UNITED States. Food & Drug Administration; GENE therapy; CELLULAR therapy; COVID-19 vaccines; AMYOTROPHIC lateral sclerosis; MONOCLONAL antibodies

The article focuses on the need for new strategies and updated operations to support the development of cell and gene therapies. It highlights the challenges faced by the Food and Drug administration (FDA) in handling the increasing number of applications for these therapies and emphasizes the importance of accelerating the approval process, adopting innovative approaches, and modernizing production methods to bring these advanced treatments to patients more efficiently and cost-effectively.